Collectively, these data highlight the importance of a wide molecular approach, aimed at defining TP53 genomic status to proper assess the risk of disease in MM patients and, concomitantly, avoid the underestimation of TP53 genomic aberrations. The gene discussed is TP53; the disease is Miyoshi myopathy.